Does anyone have an opinion on or experience with Mayne's track record on reliability of their forward looking statements? If they say generic sales will improve, should we take it at face value and rely on it?
News: MYX Mayne Pharma Expects Q4 To Be Stronger Driven By Rebound In Generic Products, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.00 |
Change
0.000(0.00%) |
Mkt cap ! $406.2M | |||
| Open | High | Low | Value | Volume |
| $4.99 | $5.07 | $4.96 | $611.9K | 122.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 3744 | $4.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.01 | 840 | 4 |
View Market Depth
| Last trade - 13.22pm 01/07/2025 (20 minute delay) ? |
| MYX (ASX) Chart |